L'intérêt à découvert pour Ensysce Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Ensysce Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Ensysce Biosciences (NASDAQ:ENSC) Stock, Rapport sur les intérêts à découvert

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

WIIM

TSLA

Tesla shares are trading higher following Q1 financial results.

STLD

Steel Dynamics shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Capital One shares are trading higher after the company reported better-than-expected Q1 adjusted EPS

News

General

Tesla CEO Musk Says Expects Time Allocation To DOGE To Drop Significantly In May; Says Next Month Will Be Devoting More Time To Tesla; Says Robotaxi Will Move Financial Needle Significantly By Middle To End Of Next Year

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.59% on an annualized basis producing an average annual return of 21.0%. Currently, Insulet has a market capitalization of $17.14 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $1,693.41 today based on a price of $244.02 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745358317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

PODD

$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today

Nuveen Insured California Premium Fund Ii

Northann Corp Receives Notice Of Non-Compliance From NYSE American

Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported first-quarter financial results Tuesday after the bell. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/g44936280/intuitive-announces-first-quarter-earnings">of the report</a>.
Q1 Earnings: Intuitive Surgical reported first-quarter revenue of $2.25 billion, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $2.19 billion, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
The robotic-assisted surgery company reported first-quarter adjusted earnings of $1.81 per share, beating analyst estimates of $1.72 per share.
Total revenue was up 19% year-over-year as Worldwide da Vinci procedures increased approximately 17%. The company said it&nbsp;placed 367 da Vinci surgical systems in the quarter, versus 313 in the prior year&#8217;s quarter. Intuitive Surgical&#8217;s da Vinci surgical system installed base grew to 10,189 systems as of March 31, up 15% year-over-year.
Intuitive Surgical ended the quarter with $9.1 billion in cash, cash equivalents and investments, up $269 million from the fourth quarter. 
&#8220;Core measures of our business were healthy this quarter, and we are pleased by continued customer adoption of our platforms, including da Vinci 5. As we look ahead, we remain focused on enabling our customers to deliver on their goals: better patient outcomes, improved patient and care team experiences, lower total cost to treat, and increased access to care,&#8221; said&nbsp;Gary Guthart, CEO of Intuitive Surgical.
Guidance:&nbsp;Intuitive Surgical expects full-year 2025 worldwide da Vinci procedures to increase approximately&nbsp;15%&nbsp;to&nbsp;17%. The company expects gross profit margin to be between&nbsp;65%&nbsp;and&nbsp;66.5%&nbsp;of revenue in 2025, which includes an estimated 1.7% impact from tariffs. 
A conference call featuring additional commentary from executives started at 4:30 p.m. ET.
ISRG Price Action: <a href="http://benzinga.com/quote/isrg">Intuitive Surgical shares</a> were down 0.99% after-hours, trading at $474 at the time of publication Tuesday, per data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal">Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal</a></li>
</ul>
Photo: Shutterstock.

Earnings

Guidance

Health Care

After-Hours Center

Movers

ISRG

Intuitive Surgical Shares Drop Following Q1 Earnings, Company Anticipates Profit Margin Impact From Tariffs

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) has outperformed the market over the past 15 years by 8.92% on an annualized basis producing an average annual return of 19.33%. Currently, Visa has a market capitalization of $638.50 billion. 
Buying $100 In V: If an investor had bought $100 of V stock 15 years ago, it would be worth $1,426.14 today based on a price of $331.00 for V at the time of writing.
<h3>Visa's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745357413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Visa 15 Years Ago Would Be Worth Today

SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/25/04/n44936302/sap-quarterly-statement-q1-2025">figures from the report. </a>
The Details: SAP reported quarterly revenue of 9.01 billion euros ($9.48 billion), beating analyst estimates, according to Benzinga Pro. Earnings of 1.44 euros ($1.54) per share also came in ahead of estimates.
Read Next: <a href="https://www.benzinga.com/25/04/44935272/tesla-reports-q1-after-the-bell-68-expect-the-company-to-miss-analysts-estimates">Will Tesla Beat The Street? 68% Expect Something Markets May Not Be Ready For</a>&nbsp;
For the first quarter, SAP reported: 
<ul>
<li>Current cloud backlog of 18.2 billion euros, up 28% and up 29% at constant currencies.</li>
<li>Cloud revenue up 27% and up 26% at constant currencies.</li>
<li>Cloud&nbsp;ERP Suite revenue up 34% and up 33% at constant currencies.</li>
<li>Total revenue up 12% and up 11% at constant currencies.</li>
<li>IFRS operating profit of 2.3 billion euros; non-IFRS operating profit of 2.5 billion euros, up 60% and up 58% at constant currencies.</li>
</ul>
&#8220;Q1 once again underlines that our success formula is working. Current cloud backlog expanded 29% at constant currencies and total revenue saw a double-digit increase. With a share of more predictable revenue of 86%, SAP&#8217;s business model remains resilient in uncertain times,&#8221; said Christian Klein, CEO of SAP. 
&#8220;Our AI-powered portfolio enables companies to navigate supply chain disruptions in over 130 countries and to unlock efficiencies with agility and speed,&#8221; Klein added.
SAP Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, SAP stock was up 8.95% after-hours at $274.99 on Tuesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty&nbsp;</a></li>
</ul>
Photo: Shutterstock

Global

Tech

SAP Shares Climb On Better-Than-Expected Q1 Results

<a href="https://www.youtube.com/watch?v=AhesolYQqiA">https://www.youtube.com/watch?v=AhesolYQqiA</a>

Politics

Economics

President Trump Says Tariff On China Will Not Be As High As 145%; Says Crypto Needs Regulatory Certainty; Says Fed Should Lower Interest Rates; Says We Would Like Chair Be Early Or On Time; Says No Intention Of Firing FED Chair

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">beating the consensus of $1.64</a>.
For FY2025, Danaher initiated adjusted EPS guidance of $7.60 to $7.75 vs. the consensus of$7.68. The company said, &#8220;We wanted to make sure everyone had an anchor point and believe having an adjusted EPS guide provides more clarity.&#8221;
Goldman Sachs writes, &#8220;DHR posted a solid quarter with Bioprocessing above expectations showing sequential order growth and book-to-bill above 1x in line with our view that Bioprocessing remains one of the more attractive areas of exposure for Tools investors. As expected, they posted a solid beat in respiratory, which should help offset some of the China IVD headwinds.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence</a>
&#8220;Also, they believe they can mitigate their own tariff impact through manufacturing flexibility and pricing, providing some comfort to investors for the sector as we start earnings season,&#8221; analyst Matthew Sykes writes.
Goldman Sachs maintains the Buy rating on Danaher, <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">with a price target of $260</a>.
Goldman Sachs expects most Tools companies this quarter to beat their first-quarter earnings but stick to their full-year guidance, essentially taking the win without raising expectations.
William Blair writes, &#8220;Despite the uncertain macro backdrop, Danaher delivered a solid first-quarter print including a healthy top-line beat driven by outperformance in bioprocessing.&#8221;
Analyst Matt Larew writes that first-quarter earnings align with what we expected based on our earlier checks. These checks showed that the bioprocessing market is steadily recovering. Analyst Larew believes the company&#8217;s decision to keep its core guidance unchanged—and even slightly raise its bioprocessing growth outlook—should be seen as a positive sign, especially given the current economic conditions.
William Blair maintains the Outperform rating.
Price Action: DHR stock is up 4.32% at $192.98 at the last check Tuesday.
Read next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44928719/verizons-subscriber-losses-raise-concerns-but-strong-business-revenue-guidance-keeps-analyst-optimistic" target="_blank" rel="noreferrer noopener">Verizon&#8217;s Subscriber Losses Raise Concerns, But Strong Business Revenue, Guidance Keeps Analyst Optimistic</a></li>
</ul>
Images: Shutterstock

Analyst Color

Analyst Ratings

Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst

Waterstone Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBF#NASDAQ">WSBF</a>) reported quarterly earnings of $0.17 per share. This is a 6.25 percent increase over earnings of $0.16 per share from the same period last year.

WSBF

Waterstone Financial Q1 EPS $0.17 Up From $0.16 YoY

BofA analyst Shaun C. Kelley reiterated a <a target="_blank" href="https://www.benzinga.com/quote/DKNG/analyst-ratings" rel="noreferrer noopener">Buy rating </a>on DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) stock on Tuesday, with a price forecast of $60.00.
The company is scheduled to release its first-quarter earnings on May 8. Ahead of its earnings report, DraftKings is expected to face investor scrutiny on its 2025 guidance and betting volume momentum.
The analyst has reduced the first-quarter EBITDA projections to $120 million from $149 million due to the lower hold during March Madness.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44800514" rel="noreferrer noopener">These Gaming Stocks Are Under Pressure As Analyst Cuts Forecast On Macau Risk And Soft Vegas Data</a>
Despite this, the full-year outlook remains intact, supported by a strong Super Bowl performance. However, the analyst noted that a ban on Texas Jackpocket could pose a $30 million EBITDA risk, possibly prompting a guidance trim to $920 million.
Market-wide same-state sports betting handle growth slowed to 9% year-over-year in the first quarter of 2025, down from 11% in the fourth quarter and 23% in the third quarter.
This deceleration and the rise of prediction markets have created uncertainty around DraftKing's forecast for mid-to-high teens growth.
While some attribute the slowdown to fewer promotions or more parlay bets, the analyst says these factors are already reflected in the company's guidance.
DraftKing's 2025 EBITDA forecast of $900 million to $1 billion currently excludes potential impacts from Missouri's sports betting rollout, possible state tax hikes, and the recent shutdown of Jackpocket in Texas.
The analyst suggests the company might revise its revenue and EBITDA guidance downward by $50 million and $30 million, respectively, due to Jackpocket.
Additionally, new taxes in states like New Jersey, Maryland, and North Carolina could pose a $60 million challenge, while Missouri's delayed launch may add $35 million.
Price Action: DKNG shares closed higher by 3.18% to $33.47 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44927810/pentair-stock-gains-after-q1-earnings-beat-implements-price-increases-to-offset-tariff-impact" target="_blank" rel="noreferrer noopener">Pentair Stock Gains After Q1 Earnings Beat, Implements Price Increases To Offset Tariff Impact</a></li>
</ul>
Photo by Lori Butcher via Shutterstock

Price Target

Reiteration

DKNG

DraftKings May Trim 2025 Forecast Amid Texas Jackpocket Shutdown: Analyst

Earnings Misses

West Fraser Timber Q1 EPS $0.46, Sales $1.46B Miss $1.54B Estimate

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) has outperformed the market over the past 15 years by 1.09% on an annualized basis producing an average annual return of 11.5%. Currently, Sea has a market capitalization of $70.50 billion. 
Buying $1000 In SE: If an investor had bought $1000 of SE stock 15 years ago, it would be worth $5,186.87 today based on a price of $119.09 for SE at the time of writing.
<h3>Sea's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745356512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Sea 15 Years Ago Would Be Worth This Much Today

Enphase Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) reported first-quarter financial results after the market close on Tuesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/04/g44936267/enphase-energy-reports-financial-results-for-the-first-quarter-of-2025">from the quarter</a>.
Q1 Earnings: Enphase Energy reported first-quarter revenue of $356.1 million, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $361.43 million. The solar company reported adjusted earnings of 68 cents per share, missing analyst estimates of 70 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was down from $382.7 million in the prior year&#8217;s quarter. U.S. revenue decreased approximately 13% on a quarter-over-quarter basis due to seasonality and &#8220;softening&#8221; U.S. demand. 
Meanwhile, revenues in Europe increased approximately 7% quarter-over-quarter, driven by higher battery sales. Enphase said it shipped approximately 1.53 microinverters, representing 170.1 megawatt hours of IQ batteries in the quarter.
The company generated&nbsp;$48.4&nbsp;million&nbsp;in cash flow from operations and $33.8 million in free cash flow during the quarter. Enphase ended the period with $1.53 billion in cash, cash equivalents, restricted cash and marketable securities.
Check This Out: <a href="https://www.benzinga.com/25/04/44930442/3-green-energy-stocks-trending-on-earth-day-2025">3 Green Energy Stocks Trending On Earth Day 2025</a>
Outlook:&nbsp;Enphase expects second-quarter revenue of $340 million to $380 million. The company anticipates a second-quarter gross margin of 42% to 45%, or 44% to 47% on an adjusted basis. The gross margin guidance includes approximately two percentage points of new tariff impacts.
Enphase Energy executives are discussing the quarter on a call with investors and analysts that kicked off at 4:30 p.m. ET.
ENPH Price Action: <a href="https://www.benzinga.com/quote/ENPH" target="_blank" rel="noreferrer noopener">Enphase shares</a> were down 12.39% after-hours, trading at $46.81 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44928828/devon-energy-unveils-1-billion-annual-optimization-plan-targets-efficiency-gains-by-2026">Devon Energy Unveils $1 Billion Annual Optimization Plan, Targets Efficiency Gains By 2026</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Sidney+van+den+Boogaard">Sidney van den Boogaard</a>/Shutterstock.

ENPH

Enphase Energy Q1 Earnings: Revenue Miss, EPS Miss, Cautious Guidance, Shares Sink

Second Quarter Outlook
"Our outlook for the second quarter is based on the assumption that the current tariff structure in place as of today (April 22, 2025) remains in place throughout the second quarter. For the second quarter, we expect core sales(1) growth to be in the low to mid-single digit range and adjusted EBITDA margin(1) in the range of 25.5% to 26.0%. We are affirming our full year guidance as our first quarter actual results and second quarter outlook put the first half of 2025 well on-track to the original full year guidance we provided in February."

Zurn Elkay Water Solutions Expects Q2 Core Sales Growth To Be In The Low To Mid-Single Digit Range And Adjusted EBITDA Margin In The Range Of 25.5% To 26.0%; Reaffirms FY25 Guidance

Preliminary First Quarter 2025 Results The following preliminary unaudited first quarter 2025 results are based on preliminary internal data available as of the date of this announcement:
<ul>
<li>Revenue of approximately €307 million to €311 million</li>
<li>Profit for the period of approximately €20 million to €24 million</li>
<li>Adjusted EBITDA1 of approximately €56 million to €58 million &nbsp;</li>
</ul>
The Company will release its full financial and operating results for the first quarter ended March 31, 2025, on Monday, May 12, 2025 and will host an earnings call via webcast to discuss the results at 8:30 a.m. Eastern time on May 12.

SRAD

Sportradar Preliminary Q1 2025 Revenue ~€307 Million To €311 Million

Sportradar Group AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) ("Sportradar" or the "Company") today announced a proposed secondary public offering of an aggregate of 23,000,000 Class A ordinary shares of the Company (the "Secondary Offering") by an affiliate of Canada Pension Plan Investment Board, an affiliate of Technology Crossover Ventures, and Carsten Koerl, the Company's Chief Executive Officer (collectively, the "Selling Shareholders"). The underwriters will have a 30-day option to purchase up to an additional 3,450,000 Class A ordinary shares from the Selling Shareholders. The Company is not selling any shares and will not receive any proceeds from the proposed Secondary Offering.
In addition, Sportradar has authorized the concurrent purchase from the underwriters of 3,000,000 Class A ordinary shares at a price per share equal to the price at which the underwriters purchase the shares from the Selling Shareholders in the Secondary Offering, up to a maximum of $75 million (the "Share Repurchase"), subject to the completion of the Secondary Offering. The Share Repurchase is part of the Company's existing $200 million share repurchase program and the Company intends to fund the Share Repurchase with cash on hand. The underwriters will not receive any underwriting fees for the shares being repurchased by the Company.
Goldman Sachs &amp; Co. LLC and J.P. Morgan are acting as joint book-running managers for the Secondary Offering.

Offerings

Buybacks

Sportradar Announces Secondary Offering Of 23M Class A Shares By Major Shareholders Including CEO Carsten Koerl; Plans to Repurchase 3M Shares For Up To $75M As Part Of $200M Buyback Program

<h3>Gainers</h3>
<ul>
<li>CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) stock moved upwards by 18.1% to $0.79 during Tuesday's after-market session. The market value of their outstanding shares is at $54.1 million. </li>
<li>AIFU (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) shares moved upwards by 7.69% to $0.14. The company's market cap stands at $7.9 million. </li>
<li>Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) shares increased by 5.83% to $94.7. The market value of their outstanding shares is at $6.5 billion. </li>
<li>AGM Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) shares moved upwards by 5.0% to $0.03. The market value of their outstanding shares is at $1.3 million. </li>
<li>Zhibao Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) stock rose 4.94% to $1.02. The market value of their outstanding shares is at $32.6 million. </li>
<li>Patriot Ntl Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNBK#NASDAQ">PNBK</a>) shares rose 3.84% to $3.24. The market value of their outstanding shares is at $238.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Top KingWin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAI#NASDAQ">WAI</a>) shares declined by 9.6% to $0.14 during Tuesday's after-market session. The company's market cap stands at $26.4 million. </li>
<li>Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) stock decreased by 5.61% to $7.41. The company's market cap stands at $406.6 million. </li>
<li>Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) shares declined by 5.09% to $11.21. The company's market cap stands at $140.6 million. </li>
<li>AppTech Payments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) stock decreased by 5.0% to $0.4. The market value of their outstanding shares is at $13.2 million. </li>
<li>Dominari Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>) shares fell 4.81% to $4.16. The market value of their outstanding shares is at $60.9 million. </li>
<li>Pineapple Financial (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#AMEX">PAPL</a>) stock fell 4.68% to $0.27. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGMH

AIFU

APCX

BPOP

DOMH

FRGE

GDOT

PAPL

PNBK

ZBAO

12 Financials Stocks Moving In Tuesday's After-Market Session

Press Releases

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Entertainment

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Comments

Ensysce Biosciences

Intérêt court

Ensysce Biosciences (NASDAQ:ENSC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL